The screen revealed a novel way to selectively kill prostate cancer cells by combining OGT inhibitor with compounds targeting the transcription elongation kinase, cyclin-dependent kinase 9 (CDK9; Itkonen et al. 2020). This evidence concerns the gene CDK9 and prostate carcinoma.